IPSEN (OTCMKTS:IPSEY) Given Consensus Rating of “Hold” by Brokerages

Shares of IPSEN (OTCMKTS:IPSEY) have been given an average rating of “Hold” by the six analysts that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating on the company.

IPSEY has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a report on Thursday, May 14th. Jefferies Financial Group lowered shares of IPSEN to an “underperform” rating in a report on Sunday. Finally, Zacks Research upgraded IPSEN to a “hold” rating in a research note on Friday, May 29th.

IPSEN Stock Performance

Shares of IPSEN stock traded up $2.59 during midday trading on Friday, hitting $47.68. The company had a trading volume of 276 shares, compared to its average volume of 781. IPSEN has a 12-month low of $30.05 and a 12-month high of $51.10. The company has a fifty day simple moving average of $45.87 and a 200 day simple moving average of $45.56.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).